{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:23Z","timestamp":1791924203400,"version":"4.3.4"},"reference-count":100,"publisher":"SAABRON PRESS","issue":"2","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Treatment of multiple myeloma (MM) has entered the era of deep remission\u2013oriented therapy, where minimal residual disease (MRD) has become a key indicator for treatment response and long-term prognosis, surpassing conventional complete remission criteria. However, the optimal integration of MRD into clinical decision-making remains to be established. This expert consensus offers evidence-based guidance on redefining treatment goals in the era of CD38-based therapy, incorporating MRD status into therapeutic decisions, standardizing MRD detection, and integrating new technologies to address current challenges. The consensus supports including MRD assessment in treatment evaluation for almost all MM patients and recommends a comprehensive approach that combines bone marrow, imaging, and peripheral blood\u2013based assessments. For patients receiving CD38-based therapy, achieving and sustaining MRD negativity is strongly linked to improved outcomes. The timing and frequency of MRD testing should be adapted to treatment phases, and CD38-based therapy may be used as part of active maintenance strategies, especially in high-risk populations. Dynamic MRD monitoring is emphasized as a critical part of disease management. Both next-generation flow and next-generation sequencing are considered interchangeable for prognostic assessment, while peripheral residual disease detection is a promising direction for future disease surveillance. This consensus provides a practical framework for integrating MRD assessment into MM clinical management. Dynamic, MRD-guided treatment strategies may enable more precise risk stratification and personalized therapy, ultimately improving long-term patient outcomes.<\/jats:p>","DOI":"10.46989\/001c.160933","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:47:39Z","timestamp":1777906059000},"source":"Crossref","is-referenced-by-count":1,"title":["Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group"],"prefix":"10.46989","volume":"8","author":[{"given":"Wenming","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chor Sang","family":"Chim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hong Kong Sanatorium Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/025yypj46","id-type":"ROR","asserted-by":"publisher"}],"name":"National University Cancer Institute, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[{"name":"Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Fu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Soochow University, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Hanamura","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Aichi Medical University, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Shang-Yi","family":"Huang","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Ishida","sequence":"additional","affiliation":[{"name":"Japanese Red Cross Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Ptushkin","sequence":"additional","affiliation":[{"name":"Botkin Moscow City Clinical Hospital, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takezako","sequence":"additional","affiliation":[{"name":"Nerima Hikarigaoka Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Siu Ming","family":"Wong","sequence":"additional","affiliation":[{"name":"Sir Y.K. Pao Centre for Cancer & Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[{"name":"University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1631511","DOI":"10.3389\/fonc.2025.1631511","article-title":"Soluble B-cell maturation antigen as a serum marker of MRD in patients with multiple myeloma","volume":"15","author":"E. A. Dean","year":"2025","journal-title":"Front Oncol"},{"issue":"4","key":"ref2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"O. Landgren","year":"2024","journal-title":"Blood"},{"issue":"3","key":"ref3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ajh.27582","article-title":"Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials","volume":"100","author":"I. Ntanasis-Stathopoulos","year":"2025","journal-title":"Am J Hematol"},{"issue":"6","key":"ref4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s11912-024-01537-2","article-title":"Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions","volume":"26","author":"M. Meseha","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"ref5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41571-025-01017-x","article-title":"Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma","volume":"22","author":"B. Paiva","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"ref6","doi-asserted-by":"publisher","first-page":"100252","DOI":"10.1016\/j.clinme.2024.100252","article-title":"Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis","volume":"24","author":"W. Xu","year":"2024","journal-title":"Clin Med (Lond)"},{"issue":"1","key":"ref7","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis","volume":"20","author":"H. Avet-Loiseau","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"ref8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1200\/JCO-24-02020","article-title":"Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials","volume":"43","author":"Q. Shi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref9","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1200\/JCO-25-00048","article-title":"Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point?","volume":"43","author":"M. V. Mateos","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051310","article-title":"The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies","volume":"14","author":"R. Colmenares","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","article-title":"Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma","volume":"13","author":"E. K. Mai","year":"2023","journal-title":"Blood Cancer J"},{"issue":"5","key":"ref12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"A. J. Cowan","year":"2022","journal-title":"JAMA"},{"issue":"7001","key":"ref13","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/bmj.311.7001.376","article-title":"Consensus methods for medical and health services research","volume":"311","author":"J. Jones","year":"1995","journal-title":"BMJ"},{"issue":"8","key":"ref14","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"S. Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"ref15","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"M. A. Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0023","article-title":"NCCN Guidelines\u00ae Multiple Myeloma (Version 2.2026)","author":"S.K. Kumar","year":"2025","journal-title":"NCCN"},{"issue":"7650","key":"ref17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"G. H. Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"9","key":"ref18","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2105\/ajph.74.9.979","article-title":"Consensus methods: characteristics and guidelines for use","volume":"74","author":"A. Fink","year":"1984","journal-title":"Am J Public Health"},{"key":"ref19","article-title":"i2TEAMM presentation to support MRD as accelerated approval endpoint.","author":"Oncologic Drugs Advisory Committee (ODAC)","year":"2024"},{"issue":"5","key":"ref20","doi-asserted-by":"publisher","first-page":"e221","DOI":"10.1016\/j.clml.2020.01.001","article-title":"Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study","volume":"20","author":"C. Kunacheewa","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"ref21","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"L. J. Costa","year":"2023","journal-title":"Lancet Haematol"},{"issue":"14","key":"ref22","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/bloodadvances.2020002037","article-title":"Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma","volume":"4","author":"J. Martinez-Lopez","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"ref23","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"S.V. Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3389\/fonc.2020.00860","article-title":"Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches","volume":"10","author":"I. V. Kostopoulos","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"ref25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.46989\/001c.92085","article-title":"Tolerability of Daratumumab Amongst Asian Patients with Plasma Cell Dyscrasias - A Single Centre Experience","volume":"6","author":"A.C.Y. Tso","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"9","key":"ref26","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3390\/cancers17091389","article-title":"Real-World Treatment Outcomes of Different Sequencing Options with Daratumumab, Lenalidomide, and Dexamethasone in Patients with Transplant-Ineligible Multiple Myeloma in Japan","volume":"17","author":"K. Suzuki","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"E","key":"ref27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3889\/oamjms.2020.3636","article-title":"Biotechnological Medicines in the Russian Pharmaceutical Market: New Pharmacopeia Requirements and the Status of Restrictive Lists","volume":"8","author":"N. Bekhorashvili","year":"2020","journal-title":"Open Access Maced J Med Sci"},{"issue":"3","key":"ref28","doi-asserted-by":"publisher","first-page":"883","DOI":"10.4143\/crt.2024.781","article-title":"Real-World Effectiveness and Safety of Intravenous Daratumumab in Patients with Multiple Myeloma: A Multicenter, Observational Study from Korea","volume":"57","author":"Y. Koh","year":"2025","journal-title":"Cancer Res Treat"},{"issue":"1","key":"ref29","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1186\/s12885-025-13925-3","article-title":"Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed\/refractory multiple myeloma","volume":"25","author":"L. Wang","year":"2025","journal-title":"BMC Cancer"},{"issue":"3","key":"ref30","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/hon.3105","article-title":"Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed\/refractory multiple myeloma: An update of the phase 1\/2 ISLANDs study","volume":"41","author":"K. Sunami","year":"2023","journal-title":"Hematol Oncol"},{"key":"ref31","article-title":"FDA approves Sarclisa\u00ae (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma","author":"Sanofi","year":"2021","journal-title":"Sanofi"},{"key":"ref32","article-title":"New drug approvals - October 2022","year":"2022","journal-title":"Health Sciences Authority"},{"key":"ref33","article-title":"Press Release Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma","author":"Sanofi","year":"2025","journal-title":"Sanofi"},{"issue":"10272","key":"ref34","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"N. van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"ref35","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10147-025-02741-1","article-title":"PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of atezolizumab for alveolar soft part sarcoma, epcoritamab for follicular lymphoma, and isatuximab for multiple myeloma in Japan","volume":"30","author":"N. Matsumura","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"ref36","article-title":"Sarclisa is the first anti-CD38 treatment in combination with standard-of-care VRd approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant","author":"Sanofi","year":"2025","journal-title":"Sanofi"},{"issue":"8","key":"ref37","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"P. Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"ref38","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood.2024027620","article-title":"Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results","volume":"146","author":"J. Corre","year":"2025","journal-title":"Blood"},{"issue":"4","key":"ref39","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"P. Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 16","key":"ref40","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1200\/JCO.2025.43.16_suppl.7501","article-title":"Subcutaneous daratumumab (Dara) + bortezomib\/lenalidomide\/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial","volume":"43","author":"P. Moreau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref41","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1200\/JCO-24-02266","article-title":"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial","volume":"43","author":"E. K. Mai","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"ref42","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","article-title":"Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"T. Facon","year":"2025","journal-title":"Leukemia"},{"issue":"4","key":"ref43","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"J. San-Miguel","year":"2022","journal-title":"Blood"},{"issue":"5","key":"ref44","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S1470-2045(25)00018-X","article-title":"Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"26","author":"M. V. Mateos","year":"2025","journal-title":"Lancet Oncol"},{"issue":"14","key":"ref45","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.3390\/cancers15143687","article-title":"Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future","volume":"15","author":"A. Medina-Herrera","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"ref46","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00277-024-05958-8","article-title":"Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study","volume":"104","author":"W. Fu","year":"2025","journal-title":"Ann Hematol"},{"issue":"17","key":"ref47","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"391","author":"T. Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"ref48","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"S. Z. Usmani","year":"2025","journal-title":"Nat Med"},{"issue":"8","key":"ref49","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial","volume":"41","author":"P. Sonneveld","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref50","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1200\/JCO.20.01814","article-title":"Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and\/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR","volume":"39","author":"H. Avet-Loiseau","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"ref51","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial","volume":"41","author":"M. A. Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref52","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study","volume":"13","author":"T. Martin","year":"2023","journal-title":"Blood Cancer J"},{"issue":"10","key":"ref53","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1016\/j.clml.2023.06.011","article-title":"Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis","volume":"23","author":"Y. Kawano","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"ref54","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.3324\/haematol.2017.169235","article-title":"Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection","volume":"102","author":"A. Oberle","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"ref55","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/bjh.20218","article-title":"Daratumumab and isatuximab differentially affect CD38 detection on plasma cells in myeloma: Anti-CD38 nanobody (clone JK36) and CD319 combination improve flow cytometric identification of plasma cells after targeted therapies","volume":"207","author":"A. Shameli","year":"2025","journal-title":"Br J Haematol"},{"key":"ref56","article-title":"Hematologic Malignancies: Regulatory considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment Guidance for Industry","author":"Center for Drug Evaluation and Research","year":"2020"},{"issue":"10","key":"ref57","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"J. Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"ref58","doi-asserted-by":"publisher","first-page":"e942","DOI":"10.1097\/HS9.0000000000000942","article-title":"Measurable residual disease testing in multiple myeloma routine clinical practice: a modified Delphi study","volume":"7","author":"K. Ramasamy","year":"2023","journal-title":"HemaSphere"},{"issue":"1","key":"ref59","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.clml.2022.10.008","article-title":"Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma","volume":"23","author":"D. M. Foureau","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"ref60","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12885-022-09184-1","article-title":"Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02\/HO95 MM trial","volume":"22","author":"A. Schmitz","year":"2022","journal-title":"BMC Cancer"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"932852","DOI":"10.3389\/fonc.2022.932852","article-title":"Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy","volume":"12","author":"V. Ferla","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"ref62","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma","volume":"38","author":"B. Paiva","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"ref63","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41408-020-0297-2","article-title":"Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma","volume":"10","author":"M. Gavriatopoulou","year":"2020","journal-title":"Blood Cancer J"},{"issue":"6","key":"ref64","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3760\/cma.j.cn121090-20240430-00167","article-title":"Chinese expert consensus on minimal residual disease detection in multiple myeloma based on bone marrow samples (2024)","volume":"45","author":"Experimental Diagnostic Group","year":"2024","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"12","key":"ref65","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3760\/cma.j.cn121090-20241111-00444","article-title":"Chinese guidelines on response assessment and minimal residual disease monitoring in multiple myeloma","volume":"45","author":"Multiple Myeloma Expert Committee of Chinese Society of Clinical Oncology (CSCO), Myeloma & Plasma Cell Disease Group, Hematology Oncology Committee of China Anti-Cancer Association (CACA)","year":"2024","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/S2152-2650(25)03451-2","article-title":"Updated Efficacy and Safety Results of Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: AURIGA Study","volume":"25","author":"L. D. Anderson","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"ref67","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/hematology.2022000348","article-title":"The burden of myeloma: novel approaches to disease assessment","volume":"2022","author":"M. Ho","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"ref68","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41408-024-01088-6","article-title":"Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN","volume":"14","author":"A. Chari","year":"2024","journal-title":"Blood Cancer J"},{"issue":"7","key":"ref69","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/2040620718775629","article-title":"Update on the role of lenalidomide in patients with multiple myeloma","volume":"9","author":"S. A. Holstein","year":"2018","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"ref70","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41408-024-01156-x","article-title":"Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)","volume":"14","author":"B. A. Derman","year":"2024","journal-title":"Blood Cancer J"},{"issue":"18","key":"ref71","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1182\/blood.2022019531","article-title":"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma","volume":"142","author":"L. Rosinol","year":"2023","journal-title":"Blood"},{"issue":"5","key":"ref72","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1016\/j.clml.2023.02.005","article-title":"Association of Minimal Residual Disease Negativity Rates With Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysis","volume":"23","author":"J. Ficek","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"801851","DOI":"10.3389\/fonc.2021.801851","article-title":"Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications","volume":"11","author":"C. Charalampous","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"ref74","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40364-021-00328-2","article-title":"Minimal residual disease in multiple myeloma: current status","volume":"9","author":"H. Ding","year":"2021","journal-title":"Biomark Res"},{"issue":"12","key":"ref75","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"M. Roshal","year":"2017","journal-title":"Blood Adv"},{"issue":"10","key":"ref76","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma","volume":"10","author":"A. Medina","year":"2020","journal-title":"Blood Cancer J"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1182\/blood-2021-146441","article-title":"Prospective Comparison Study of Prognostic Value of MRD Detected By 8-Color MFC (EuroFlow-NGF) and NGS in Patients with Multiple Myeloma in ASCT Setting","volume":"138","author":"T. Yoroidaka","year":"2021","journal-title":"Blood"},{"issue":"1","key":"ref78","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-020-00911-4","article-title":"Measurable residual disease in multiple myeloma: ready for clinical practice?","volume":"13","author":"L. Burgos","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"ref79","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s12672-024-00938-w","article-title":"Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma","volume":"15","author":"M. Zhou","year":"2024","journal-title":"Discov Oncol"},{"issue":"3","key":"ref80","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1182\/bloodadvances.2024014417","article-title":"MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma","volume":"9","author":"M. Bhutani","year":"2025","journal-title":"Blood Adv"},{"issue":"20","key":"ref81","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma","volume":"125","author":"B. Paiva","year":"2015","journal-title":"Blood"},{"issue":"24","key":"ref82","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy","volume":"134","author":"L. Sanoja-Flores","year":"2019","journal-title":"Blood"},{"issue":"7","key":"ref83","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/COC.0000000000001197","article-title":"Advancing MRD Detection in Multiple Myeloma: Technologies, Applications, and Future Perspectives","volume":"48","author":"B. Chen","year":"2025","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"ref84","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1002\/hem3.63","article-title":"Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant","volume":"8","author":"P. R. Tembhare","year":"2024","journal-title":"Hemasphere"},{"issue":"23","key":"ref85","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1182\/blood.2024024995","article-title":"Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma","volume":"144","author":"N. Puig","year":"2024","journal-title":"Blood"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1182\/blood-2025-2201","article-title":"Real world test characteristics of mass spectrometry monoclonal protein monitoring in multiple myeloma","volume":"146","author":"K. Shim","year":"2025","journal-title":"Blood"},{"issue":"6","key":"ref87","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1158\/1078-0432.CCR-23-2767","article-title":"Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)","volume":"30","author":"H. Fan","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"23","key":"ref88","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"A. Perrot","year":"2018","journal-title":"Blood"},{"issue":"23","key":"ref89","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"N. C. Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"ref90","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma","volume":"137","author":"I. Goicoechea","year":"2021","journal-title":"Blood"},{"issue":"1","key":"ref91","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12885-024-12077-0","article-title":"Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma","volume":"24","author":"Y. Tao","year":"2024","journal-title":"BMC Cancer"},{"issue":"3","key":"ref92","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/bjh.18211","article-title":"Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma","volume":"198","author":"H. Cho","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"ref93","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12672-024-00891-8","article-title":"Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma","volume":"15","author":"J. Wang","year":"2024","journal-title":"Discov Oncol"},{"issue":"7","key":"ref94","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2023022083","article-title":"Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma","volume":"143","author":"C. Guerrero","year":"2024","journal-title":"Blood"},{"issue":"7","key":"ref95","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1182\/blood.2023022080","article-title":"Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma","volume":"143","author":"M. D'Agostino","year":"2024","journal-title":"Blood"},{"issue":"1","key":"ref96","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/ejh.14316","article-title":"Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry","volume":"114","author":"L. Muronova","year":"2025","journal-title":"Eur J Haematol"},{"issue":"12","key":"ref97","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.3324\/haematol.2024.285742","article-title":"Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial","volume":"109","author":"N. Puig","year":"2024","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"ref98","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/blood-2022-167382","article-title":"Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow","volume":"140","author":"L. Notarfranchi","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"ref99","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1182\/blood-2023-186916","article-title":"Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)","volume":"142","author":"C. Gonzalez","year":"2023","journal-title":"Blood"},{"issue":"1","key":"ref100","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis","volume":"3","author":"N. C. Munshi","year":"2017","journal-title":"JAMA Oncol"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/160933-guidelines-and-consensus-for-minimal-residual-disease-adapted-therapy-in-multiple-myeloma-from-the-pan-pacific-multiple-myeloma-working-group","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:26:46Z","timestamp":1779794806000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/160933-guidelines-and-consensus-for-minimal-residual-disease-adapted-therapy-in-multiple-myeloma-from-the-pan-pacific-multiple-myeloma-working-group"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":100,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.160933","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]}}}